These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1192 related articles for article (PubMed ID: 7656272)

  • 1. Generation of human-melanoma-specific T lymphocyte clones defining novel cytolytic targets with panels of newly established melanoma cell lines.
    Kirkin AF; Petersen TR; Olsen AC; Li L; thor Straten P; Zeuthen J
    Cancer Immunol Immunother; 1995 Aug; 41(2):71-81. PubMed ID: 7656272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cellular immune response to human renal-cell carcinomas: definition of a common antigen recognized by HLA-A2-restricted cytotoxic T-lymphocyte (CTL) clones.
    Bernhard H; Karbach J; Wölfel T; Busch P; Störkel S; Stöckle M; Wölfel C; Seliger B; Huber C; Meyer zum Büschenfelde KH
    Int J Cancer; 1994 Dec; 59(6):837-42. PubMed ID: 7989126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative correlation between HLA class I allele expression and recognition of melanoma cells by antigen-specific cytotoxic T lymphocytes.
    Rivoltini L; Barracchini KC; Viggiano V; Kawakami Y; Smith A; Mixon A; Restifo NP; Topalian SL; Simonis TB; Rosenberg SA
    Cancer Res; 1995 Jul; 55(14):3149-57. PubMed ID: 7541714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. T cell receptor (TCR) structure of autologous melanoma-reactive cytotoxic T lymphocyte (CTL) clones: tumor-infiltrating lymphocytes overexpress in vivo the TCR beta chain sequence used by an HLA-A2-restricted and melanocyte-lineage-specific CTL clone.
    Sensi M; Salvi S; Castelli C; Maccalli C; Mazzocchi A; Mortarini R; Nicolini G; Herlyn M; Parmiani G; Anichini A
    J Exp Med; 1993 Oct; 178(4):1231-46. PubMed ID: 8376931
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor associated antigens in human renal cell carcinoma: MHC restricted recognition by cytotoxic T lymphocytes.
    Bernhard H; Jäger E; Maeurer MJ; Meyer zum Büschenfelde KH; Knuth A
    Tissue Antigens; 1996 Jul; 48(1):22-31. PubMed ID: 8864171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Melanoma cells and normal melanocytes share antigens recognized by HLA-A2-restricted cytotoxic T cell clones from melanoma patients.
    Anichini A; Maccalli C; Mortarini R; Salvi S; Mazzocchi A; Squarcina P; Herlyn M; Parmiani G
    J Exp Med; 1993 Apr; 177(4):989-98. PubMed ID: 8459226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lysis of human melanoma cells by autologous cytolytic T cell clones. Identification of human histocompatibility leukocyte antigen A2 as a restriction element for three different antigens.
    Wölfel T; Klehmann E; Müller C; Schütt KH; Meyer zum Büschenfelde KH; Knuth A
    J Exp Med; 1989 Sep; 170(3):797-810. PubMed ID: 2788708
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A human melanoma cell line, recognized by both HLA class I and class II restricted T cells, is capable of initiating both primary and secondary immune responses.
    Olsen AC; Fossum B; Kirkin AF; Zeuthen J; Gaudernack G
    Scand J Immunol; 1995 Apr; 41(4):357-64. PubMed ID: 7899823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recognition of shared melanoma antigen by HLA-A2-restricted cytolytic T cell clones derived from human tumor-infiltrating lymphocytes.
    Viret C; Davodeau F; Guilloux Y; Bignon JD; Semana G; Breathnach R; Jotereau F
    Eur J Immunol; 1993 Jan; 23(1):141-6. PubMed ID: 8419164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MHC-restricted recognition of autologous melanoma by tumor-specific cytotoxic T cells. Evidence for restriction by a dominant HLA-A allele.
    Crowley NJ; Darrow TL; Quinn-Allen MA; Seigler HF
    J Immunol; 1991 Mar; 146(5):1692-9. PubMed ID: 1671580
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytotoxic T-lymphocyte clones from different patients display limited T-cell-receptor variable-region gene usage in HLA-A2-restricted recognition of the melanoma antigen Melan-A/MART-1.
    Sensi M; Traversari C; Radrizzani M; Salvi S; Maccalli C; Mortarini R; Rivoltini L; Farina C; Nicolini G; Wölfel T
    Proc Natl Acad Sci U S A; 1995 Jun; 92(12):5674-8. PubMed ID: 7777568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of MAGE-3-specific cytolytic T lymphocytes in human leukocyte antigen-A2 melanoma patients.
    Valmori D; Liénard D; Waanders G; Rimoldi D; Cerottini JC; Romero P
    Cancer Res; 1997 Feb; 57(4):735-41. PubMed ID: 9044853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of HLA class I antigens in recognition of melanoma cells by tumor-specific cytotoxic T lymphocytes. Evidence for shared tumor antigens.
    Darrow TL; Slingluff CL; Seigler HF
    J Immunol; 1989 May; 142(9):3329-35. PubMed ID: 2785141
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of antigens recognized on human melanoma cells by A2-restricted cytolytic T lymphocytes (CTL).
    Wölfel T; Hauer M; Klehmann E; Brichard V; Ackermann B; Knuth A; Boon T; Meyer Zum Büschenfelde KH
    Int J Cancer; 1993 Sep; 55(2):237-44. PubMed ID: 7690346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Melanomas with concordant loss of multiple melanocytic differentiation proteins: immune escape that may be overcome by targeting unique or undefined antigens.
    Slingluff CL; Colella TA; Thompson L; Graham DD; Skipper JC; Caldwell J; Brinckerhoff L; Kittlesen DJ; Deacon DH; Oei C; Harthun NL; Huczko EL; Hunt DF; Darrow TL; Engelhard VH
    Cancer Immunol Immunother; 2000 Mar; 48(12):661-72. PubMed ID: 10752474
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HLA restriction and T-cell-receptor V beta gene expression of cytotoxic T lymphocytes reactive with human squamous-cell carcinoma of the head and neck.
    Yasumura S; Weidmann E; Hirabayashi H; Johnson JT; Herberman RB; Whiteside TL
    Int J Cancer; 1994 May; 57(3):297-305. PubMed ID: 8168988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isolation of naturally processed peptides recognized by cytolytic T lymphocytes (CTL) on human melanoma cells in association with HLA-A2.1.
    Wölfel T; Schneider J; Meyer Zum Büschenfelde KH; Rammensee HG; Rötzschke O; Falk K
    Int J Cancer; 1994 May; 57(3):413-8. PubMed ID: 8169004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes.
    Jäger E; Chen YT; Drijfhout JW; Karbach J; Ringhoffer M; Jäger D; Arand M; Wada H; Noguchi Y; Stockert E; Old LJ; Knuth A
    J Exp Med; 1998 Jan; 187(2):265-70. PubMed ID: 9432985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recognition of neuroectodermal tumors by melanoma-specific cytotoxic T lymphocytes: evidence for antigen sharing by tumors derived from the neural crest.
    Shamamian P; Mancini M; Kawakami Y; Restifo NP; Rosenberg SA; Topalian SL
    Cancer Immunol Immunother; 1994 Aug; 39(2):73-83. PubMed ID: 7519127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of melanoma antigen-specific cytotoxic T lymphocytes in vitro by stimulation with B7-expressing human melanoma cell lines.
    Fenton RG; Turcovski-Corrales SM; Taub DD
    J Immunother; 1998 Mar; 21(2):95-108. PubMed ID: 9551360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 60.